Lbp Am Sa Increases Position in Zoetis Inc. $ZTS

Key Points

• Lbp Am Sa increased its holdings in Zoetis Inc. by 7.4%, now owning 112,534 shares worth approximately $17.55 million.
• Zoetis recently reported earnings of $1.76 per share for the quarter, exceeding analysts' expectations, along with revenue of $2.46 billion.
• Wall Street analysts have a consensus rating of "Moderate Buy" for Zoetis, with an average price target of $200.88.

Lbp Am Sa lifted its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 7.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 112,534 shares of the company's stock after purchasing an additional 7,747 shares during the period. Lbp Am Sa's holdings in Zoetis were worth $17,550,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Lindbrook Capital LLC increased its position in shares of Zoetis by 1.8% during the first quarter. Lindbrook Capital LLC now owns 3,715 shares of the company's stock worth $612,000 after acquiring an additional 65 shares during the period. Scott & Selber Inc. increased its position in shares of Zoetis by 0.6% during the second quarter. Scott & Selber Inc. now owns 11,652 shares of the company's stock worth $1,817,000 after acquiring an additional 67 shares during the period. Secure Asset Management LLC increased its position in shares of Zoetis by 2.9% during the second quarter. Secure Asset Management LLC now owns 2,448 shares of the company's stock worth $382,000 after acquiring an additional 68 shares during the period. Quotient Wealth Partners LLC increased its position in shares of Zoetis by 2.3% during the first quarter. Quotient Wealth Partners LLC now owns 3,167 shares of the company's stock worth $521,000 after acquiring an additional 72 shares during the period. Finally, Broadway Wealth Solutions Inc. increased its position in shares of Zoetis by 4.4% during the first quarter. Broadway Wealth Solutions Inc. now owns 1,746 shares of the company's stock worth $287,000 after acquiring an additional 73 shares during the period. Hedge funds and other institutional investors own 92.80% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and cut their price objective for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Leerink Partnrs lowered Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Piper Sandler increased their target price on Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Leerink Partners lowered Zoetis from an "outperform" rating to a "market perform" rating and dropped their target price for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Finally, Argus reissued a "buy" rating and issued a $190.00 target price on shares of Zoetis in a report on Tuesday, September 9th. Five equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $200.88.

Zoetis Price Performance

Shares of ZTS opened at $146.12 on Wednesday. Zoetis Inc. has a fifty-two week low of $139.34 and a fifty-two week high of $196.55. The company has a market capitalization of $64.76 billion, a price-to-earnings ratio of 25.15, a price-to-earnings-growth ratio of 2.30 and a beta of 0.88. The firm has a 50-day simple moving average of $150.16 and a 200-day simple moving average of $155.45. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. During the same quarter in the prior year, the firm earned $1.56 earnings per share. The business's quarterly revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.